Health Professionals

The study is now fully recruited and in the follow up phase.

Why are we doing this study?

We are doing this research because we want to improve the treatment of patients with ischaemic heart disease (IHD). The study will investigate whether adding up to 600mg allopurinol daily to the medication of patients with IHD, will reduce their risk of having a stroke, heart attack or of dying due to cardiovascular disease. We will also measure quality of life and the cost-effectiveness of allopurinol treatment in IHD.

How will this study help?

The results of this study could have major benefits for patients and result in significant cost savings for the NHS if allopurinol is found to be effective, as it would be inexpensive and easy to introduce quickly to patient care within the UK.

How many patients will be involved?

5,215 patients across Scotland and England will be involved in the study. We hope to include approximately 10-20 patients in each of the 300 GP practices taking part.

Which patients can take part?

Patients aged 60 years or over, with a diagnosis of angina or myocardial infarction at any time or other evidence of ischaemic heart disease. Patients with severe renal impairment or who already have gout cannot take part.

Who is running this study?

The ALL-HEART study is being run by the University of Dundee and NHS Tayside, working closely with Nottingham University Hospitals NHS Trust, and other University and NHS Centres across Scotland and England. The Chief Investigator is Dr Isla Mackenzie, Dundee.

The team running this study has a lot of experience in running large clinical studies and already works with more than 700 general practices.

Who is funding this study?

The ALL-HEART study is being funded by the National Institute for Health Research, Health Technology Assessment Program (NIHR HTA).

For more information please contact us by calling (01382) 383119, or email us at